T lymphocyte engineering ex vivo for cancer and infectious disease

Bibliography

• Kaech SM, Ahmed R. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol 2001;2(5):415-22
   PubMed Web of Science ®Google Scholar
• Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Ann Rev Immunol 2004;22:745-63
   PubMed Web of Science ®Google Scholar
• Fearon DT, Manders P, Wagner SD. Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. Science 2001;293(5528):248-50
   PubMed Web of Science ®Google Scholar
• Opferman JT, Ober BT, Shton-Rickardt PG. Linear differentiation of cytotoxic effectors into memory T lymphocytes. Science 1999;283(5408):1745-8
   PubMed Web of Science ®Google Scholar
• Bouneaud C, Garcia Z, Kourilsky P, Pannetier C. Lineage relationships, homeostasis, and recall capacities of central- and effector-memory CD8 T cells in vivo. J Exp Med 2005;201(4):579-90
   PubMed Web of Science ®Google Scholar
• Chang JT, Palanivel VR, Kinjyo I, et al. Asymmetric T lymphocyte division in the initiation of adaptive immune responses. Science 2007;315(5819):1687-91
   PubMed Web of Science ®Google Scholar
• Maus MV, Kovacs B, Kwok WW, et al. Extensive replicative capacity of human central memory T cells. J Immunol 2004;172(11):6675-83
   PubMed Web of Science ®Google Scholar
• Weng NP, Palmer LD, Levine BL, et al. Tales of tails: regulation of telomere length and telomerase activity during lymphocyte development, differentiation, activation, and aging. Immunol Rev 1997;160:43-54
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401(6754):708-12
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Gattinoni L, Torabi-Parizi P, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 2005;102(27):9571-6
   PubMed Web of Science ®Google Scholar
• Monteiro J, Batliwalla F, Ostrer H, Gregersen PK. Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28+CD8+ counterparts. J Immunol 1996;156(10):3587-90
   PubMed Web of Science ®Google Scholar
• Van den Hove LE, Van Gool SW, Vandenberghe P, et al. CD57+/CD28- T cells in untreated hemato-oncological patients are expanded and display a Th1-type cytokine secretion profile, ex vivo cytolytic activity and enhanced tendency to apoptosis. Leukemia 1998;12(10):1573-82
   PubMed Web of Science ®Google Scholar
• Barber DL, Wherry EJ, Ahmed R. Cutting edge: rapid in vivo killing by memory CD8 T cells. J Immunol 2003;171(1):27-31
   PubMed Web of Science ®Google Scholar
• Sprent J, Surh CD. T cell memory. Ann Rev Immunol 2002;20:551-79
   PubMed Web of Science ®Google Scholar
• Bevan MJ. Helping the CD8(+) T-cell response. Nat Rev Immunol 2004;4(8):595-602
   PubMed Web of Science ®Google Scholar
• Ossendorp F, Mengede E, Camps M, et al. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998;187(5):693-702
   PubMed Web of Science ®Google Scholar
• Schoenberger SP, Toes RE, van d V, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998;393(6684):480-3
   PubMed Web of Science ®Google Scholar
• Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002;99(25):16168-73
   PubMed Web of Science ®Google Scholar
• Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002;99(11):3916-22
   PubMed Web of Science ®Google Scholar
• Rapoport AP, Stadtmauer EA, Aqui N, et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 2005;11(11):1230-7
   PubMed Web of Science ®Google Scholar
• Jiang H, Chess L. An integrated view of suppressor T cell subsets in immunoregulation. J Clin Invest 2004;114(9):1198-208
   PubMed Web of Science ®Google Scholar
• Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163(10):5211-8
   PubMed Web of Science ®Google Scholar
• Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006;203(7):1701-11
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Levine BL, Nasta S, et al. Adoptive immunotherapy with autologous CD25-depleted and CD3/CD28-costimulated T-cells (ACTC) enhances numeric and functional lymphocyte recovery after cyclophosphamide – fludarabine chemotherapy in patients with low-grade follicular lymphoma. Blood 2007;110(11):126
   Web of Science ®Google Scholar
• Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61(12):4766-72
   PubMed Web of Science ®Google Scholar
• Loren AW, Bunin GR, Boudreau C, et al. Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006;12(7):758-69
   PubMed Web of Science ®Google Scholar
• Fowler DH, Odom J, Steinberg SM, et al. Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006;12(11):1150-60
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Bunin N, et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 2006;107(4):1325-31
   PubMed Web of Science ®Google Scholar
• June CH, Blazar BR. Clinical application of expanded CD4+25+ cells. Semin Immunol 2006;18(2):78-88
   PubMed Web of Science ®Google Scholar
• Kono K, Takahashi A, Ichihara F, et al. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res 2002;8(6):1767-71
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298(5594):850-4
   PubMed Web of Science ®Google Scholar
• Chang AE, Aruga A, Cameron MJ, et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 1997;15(2):796-807
   PubMed Web of Science ®Google Scholar
• Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000;356(9232):802-7
   PubMed Web of Science ®Google Scholar
• Feuerer M, Beckhove P, Bai L, et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 2001;7(4):452-8
   PubMed Web of Science ®Google Scholar
• Choi C, Witzens M, Bucur M, et al. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood 2005;105(5):2132-4
   PubMed Web of Science ®Google Scholar
• Schmitz-Winnenthal FH, Volk C, Z'graggen K, et al. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res 2005;65(21):10079-87
   PubMed Web of Science ®Google Scholar
• Noonan K, Matsui W, Serafini P, et al. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res 2005;65(5):2026-34
   PubMed Web of Science ®Google Scholar
• Trickett A, Dwyer J, Tedla N, Lam-Po-Tang R. Safety and feasibility of harvesting cells for adoptive immunotherapy from patients with asymptomatic HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12(5):523-4
   PubMedGoogle Scholar
• Korbling M, Giralt S, Khouri I, et al. Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis. J Clin Apher 2001;16(2):82-7
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348(3):203-13
   PubMed Web of Science ®Google Scholar
• Germeau C, Ma W, Schiavetti F, et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 2005;201(2):241-8
   PubMed Web of Science ®Google Scholar
• Molldrem JJ. Vaccinating transplant recipients. Nat Med 2005;11(11):1162-3
   PubMed Web of Science ®Google Scholar
• Powell DJ Jr, Dudley ME, Hogan KA, et al. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol 2006;177(9):6527-39
   PubMed Web of Science ®Google Scholar
• Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006;134(1):64-76
   PubMed Web of Science ®Google Scholar
• Schultze JL, Michalak S, Seamon MJ, et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997;100(11):2757-65
   PubMed Web of Science ®Google Scholar
• Yee C, Thompson JA, Roche P, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J Exp Med 2000;192(11):1637-44
   PubMed Web of Science ®Google Scholar
• Mackensen A, Meidenbauer N, Vogl S, et al. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 2006;24(31):5060-9
   PubMed Web of Science ®Google Scholar
• Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333(16):1038-44
   PubMed Web of Science ®Google Scholar
• Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992;257:238-41
   PubMed Web of Science ®Google Scholar
• Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995;345(8941):9-13
   PubMed Web of Science ®Google Scholar
• Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2(5):551-5
   PubMed Web of Science ®Google Scholar
• Bollard CM, Savoldo B, Rooney CM, Heslop HE. Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. Acta Haematol 2003;110(2-3):139-48
   PubMed Web of Science ®Google Scholar
• Khanna R, Bell S, Sherritt M, et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA 1999;96(18):10391-6
   PubMed Web of Science ®Google Scholar
• Gottschalk S, Heslop HE, Roon CM. Treatment of Epstein-Barr virus-associated malignancies with specific T cells. Adv Cancer Res 2002;84:175-201
   PubMed Web of Science ®Google Scholar
• Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006;12(10):1160-6
   PubMed Web of Science ®Google Scholar
• Brodie SJ, Patterson BK, Lewinsohn DA, et al. HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J Clin Invest 2000;105(10):1407-17
   PubMed Web of Science ®Google Scholar
• Tan R, Xu X, Ogg GS, et al. Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome. Blood 1999;93(5):1506-10
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159-66
   PubMed Web of Science ®Google Scholar
• Figlin RA, Thompson JA, Bukowski RM, et al. Multicenter, randomized, Phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 1999;17(8):2521-9
   PubMed Web of Science ®Google Scholar
• Dreno B, Nguyen JM, Khammari A, et al. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 2002;51(10):539-46
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23(10):2346-57
   PubMed Web of Science ®Google Scholar
• Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005;102(51):18538-43
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Shelton TE, et al. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003;26(4):332-42 (1997)
   PubMed Web of Science ®Google Scholar
• Muul LM, Tuschong LM, Soenen SL, et al. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood 2003;101(7):2563-9
   PubMed Web of Science ®Google Scholar
• Mitsuyasu RT, Anton PA, Deeks SG, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4ζ gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 2000;96(3):785-93
   PubMed Web of Science ®Google Scholar
• van Lunzen J, Glaunsinger T, Stahmer I, et al. Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther 2007;15(5):1024-33
   PubMed Web of Science ®Google Scholar
• Cavazzana-Calvo M, Hacein-Bey S, de Saint BG, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000;288(5466):669-72
   PubMed Web of Science ®Google Scholar
• Available from: www.esgct.org/upload/X-SCID_statement_AT.pdf
   Google Scholar
• Thrasher AJ, Gaspar HB, Baum C, et al. Gene therapy: X-SCID transgene leukaemogenicity. Nature 2006;443(7109):E5-6
   Web of Science ®Google Scholar
• Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302(5644):415-9
   PubMed Web of Science ®Google Scholar
• Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 2006;103(46):17372-7
   PubMed Web of Science ®Google Scholar
• Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006;24(6):687-96
   PubMed Web of Science ®Google Scholar
• Urnov FD, Miller JC, Lee YL, et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005;435(7042):646-51
   PubMed Web of Science ®Google Scholar
• Perez E, Jouvenot Y, Miller JC, et al. Towards gene knock out therapy for AIDS/HIV: targeted disruption of CCR5 using engineered Zinc Finger Protein Nucleases (ZFNs). Mol Ther 2007;13:S293
   Google Scholar
• Eshhar Z, Waks T, Bendavid A, Schindler DG. Functional expression of chimeric receptor genes in human T cells. J Immunol Methods 2001;248(1-2):67-76
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Westwood JA, Parker LL, et al. A Phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006;12(20 Pt 1):6106-15
   PubMed Web of Science ®Google Scholar
• Park JR, DiGiusto DL, Slovak M, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007;15(4):825-33
   PubMed Web of Science ®Google Scholar
• Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006;24(13):e20-2
   PubMedGoogle Scholar
• Loskog A, Giandomenico V, Rossig C, et al. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 2006;20(10):1819-28
   PubMed Web of Science ®Google Scholar
• Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003;3(1):35-45
   PubMed Web of Science ®Google Scholar
• Riley JL, June CH. The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood 2005;105(1):13-21
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314(5796):126-9
   PubMed Web of Science ®Google Scholar
• Heemskerk MH, Hagedoorn RS, van der Hoorn MA, et al. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood 2007;109(1):235-43
   PubMed Web of Science ®Google Scholar
• Thomas S, Hart DP, Xue SA, et al. T-cell receptor gene therapy for cancer: the progress to date and future objectives. Expert Opin Biol Ther 2007;7(8):1207-18
   PubMed Web of Science ®Google Scholar
• Berger C, Berger M, Feng J, Riddell SR. Genetic modification of T cells for immunotherapy. Expert Opin Biol Ther 2007;7(8):1167-82
   PubMed Web of Science ®Google Scholar
• Evans LS, Witte PR, Feldhaus AL, et al. Expression of chimeric granulocyte-macrophage colony-stimulating factor/interleukin 2 receptors in human cytotoxic T lymphocyte clones results in granulocyte-macrophage colony-stimulating factor-dependent growth. Hum Gene Ther 1999;10(12):1941-51
   PubMed Web of Science ®Google Scholar
• Topp MS, Riddell SR, Akatsuka Y, et al. Restoration of CD28 expression in CD28- CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production. J Exp Med 2003;198(6):947-55
   PubMed Web of Science ®Google Scholar
• Rufer N, Migliaccio M, Antonchuk J, et al. Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential. Blood 2001;98(3):597-603
   PubMed Web of Science ®Google Scholar
• Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997;276(5319):1719-24
   PubMed Web of Science ®Google Scholar
• Ciceri F, Bonini C, Marktel S, et al. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 2007;109(11):4698-707
   PubMed Web of Science ®Google Scholar
• Riddell SR, Elliott M, Lewinsohn DA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996;2(2):216-23
   PubMed Web of Science ®Google Scholar
• Berger C, Flowers ME, Warren EH, Riddell SR. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 2006;107(6):2294-302
   PubMed Web of Science ®Google Scholar
• Clackson T, Yang W, Rozamus LW, et al. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci USA 1998;95(18):10437-42
   PubMed Web of Science ®Google Scholar
• Straathof KC, Spencer DM, Sutton RE, Rooney CM. Suicide genes as safety switches in T lymphocytes. Cytotherapy 2003;5(3):227-30
   PubMed Web of Science ®Google Scholar
• Levine BL, Ueda Y, Craighead N, et al. CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro. Int Immunol 1995;7(6):891-904
   PubMed Web of Science ®Google Scholar
• Levine BL, Bernstein WB, Connors M, et al. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol 1997;159(12):5921-30
   PubMed Web of Science ®Google Scholar
• Levine BL, Mosca JD, Riley JL, et al. Antiviral effect and ex vivo CD4+ T cell proliferation in HIV- positive patients as a result of CD28 costimulation. Science 1996;272(5270):1939-43
   PubMed Web of Science ®Google Scholar
• Carroll RG, Riley JL, Levine BL, et al. Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. Science 1997;276(5310):273-6
   PubMed Web of Science ®Google Scholar
• Renner C, Ohnesorge S, Held G, et al. T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood 1996;88(1):236-41
   PubMed Web of Science ®Google Scholar
• Bonyhadi M, Frohlich M, Rasmussen A, et al. In vitro engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemia. J Immunol 2005;174(4):2366-75
   PubMed Web of Science ®Google Scholar
• Maus MV, Thomas AK, Leonard DG, et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 2002;20(2):143-8
   PubMed Web of Science ®Google Scholar
• Thomas AK, Maus MV, Shalaby WS, et al. A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. Clin Immunol 2002;105(3):259-72
   PubMed Web of Science ®Google Scholar
• Suhoski MM, Golovina TN, Aqui NA, et al. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther 2007;15(5):981-8
   PubMed Web of Science ®Google Scholar
• Smith B, Kasamon YL, Miller CB, et al. K562/GM-CSF vaccination reduces tumor burden, including achieving molecular remissions, in chronic myeloid leukemia (CML) patients (PTS) with residual disease on imatinib mesylate (IM). J Clin Oncol 2006;24(18S):6509
   Google Scholar
• Broeren CP, Gray GS, Carreno BM, June CH. Costimulation light: activation of CD4+ T cells with CD80 or CD86 rather than anti-CD28 leads to a Th2 cytokine profile. J Immunol 2000;165(12):6908-14
   PubMed Web of Science ®Google Scholar
• Godfrey WR, Ge YG, Spoden DJ, et al. In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood 2004;104(2):453-61
   PubMed Web of Science ®Google Scholar
• Walker RE, Bechtel CM, Natarajan V, et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 2000;96(2):467-74
   PubMed Web of Science ®Google Scholar
• Levine BL, Cotte J, Small CC, et al. Large scale production of CD4+ T cells from HIV-1 infected donors following CD3/CD28 costimulation. J Hematotherapy 1998;7:437-48
   PubMedGoogle Scholar
• Burger SR. Current regulatory issues in cell and tissue therapy. Cytotherapy 2003;5(4):289-98
   PubMed Web of Science ®Google Scholar
• Cross P, Levine BL. Assays for the release of cellular gene therapy products. In: Concepts in Genetic Medicine. Dropulic B, Carter B, editors. Hoboken, NJ, John Wiley & Sons; 2008
   Google Scholar
• Rapoport AP, Levine BL, Badros A, et al. Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells. Bone Marrow Transplant 2004;33(1):53-60
   PubMed Web of Science ®Google Scholar
• Andreadis C, Levine BL, Nasta SD, et al. Adaptive immunotherapy with autologous CD25-depleted and CD3/CD28-costimulated T-cells enhances lymphocyte recovery after cyclophosphamide – fludarabine chemotherapy in patients with low-grade follicular lymphoma. Blood 2006;108(11):2717
   Google Scholar
• Levine BL, Bernstein WB, Aronson NE, et al. Adoptive transfer of costimulated CD4(+) T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med 2002;8(1):47-53
   PubMed Web of Science ®Google Scholar
• Kohn DB. Lentiviral vectors ready for prime-time. Nat Biotechnol 2007;25(1):65-6
   PubMed Web of Science ®Google Scholar